(Q54640859)

2 June 2018

title

The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. (English)

1 reference

2 June 2018

metastatic renal cell carcinoma

1 reference

1 reference

Naveen S Basappa

1

1 reference

2 June 2018

Paul Elson

2

1 reference

2 June 2018

Ali-Reza Golshayan

3

1 reference

2 June 2018

Laura Wood

4

1 reference

2 June 2018

Jorge A Garcia

5

1 reference

2 June 2018

Robert Dreicer

6

1 reference

2 June 2018

Brian I Rini

7

1 reference

2 June 2018

language of work or name

English

0 references

publication date

19 October 2010

1 reference

2 June 2018

published in

Cancer

1 reference

2 June 2018

volume

117

1 reference

2 June 2018

issue

6

1 reference

2 June 2018

page(s)

1183-1189

1 reference

2 June 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25713

Sunitinib efficacy against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25713

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25713

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25713

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25713

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25713

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25713

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25713

Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25713

Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25713

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25713

Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25713

Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25713

21 January 2018

Identifiers

DOI

10.1002/CNCR.25713

1 reference

2 June 2018

PubMed ID

20960527

1 reference

2 June 2018